FETZIMA 120 MG — DIN 02441004
LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) : 120 MG · ABBVIE CORPORATION · CAPSULE (EXTENDED RELEASE) · wholesale supply in Canada
Health Canada status: MARKETED
What is FETZIMA?
FETZIMA 120 MG contains LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) : 120 MG. It is listed in the Health Canada Drug Product Database under DIN 02441004, held by ABBVIE CORPORATION, supplied as CAPSULE (EXTENDED RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 04-Mar-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FETZIMA used for?
FETZIMA (levomilnacipran extended release capsules) is indicated for the symptomatic relief of major depressive disorder (MDD).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Levomilnacipran in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Levomilnacipran — 4 DINs, of which 4 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ABBVIE CORPORATION | 4 | 4 | FETZIMA | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 120 MG |
|---|---|
| Dosage form | CAPSULE (EXTENDED RELEASE) |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 30 capsules: 20 mg, 40 mg, 80 mg and 120 mg. |
| Storage | FETZIMA should be stored at controlled room temperature (15-30°C). Keep out of reach and sight of children. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Levomilnacipran |
|---|---|
| ATC code | N06AX28 |
| AHFS class | 28:16.04.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02441004 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2441004 |
| Brand name | FETZIMA |
| Generic / active ingredient | LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) : 120 MG |
| Market authorization holder | ABBVIE CORPORATION |
| Health Canada schedule | Prescription |
| ATC code | N06AX28 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N06AX |
| Current status | MARKETED |
| Status date | 04-Mar-2024 |
| Original market date | 2016-04-22 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: The recommended dose range for FETZIMA is 40 mg to 120 mg once daily. FETZIMA should be initiated at 20 mg once daily for 2 days and then increased to 40 mg once daily. If the physician decides a dose increase above 40 mg/day is warranted, the dose may be increased in increments of 40 mg. The maximum recommended dose should not exceed 120 mg/day. FETZIMA should be taken at approximately the same time each day, swallowed whole (do not open, chew or crush the capsule), and can be taken with or without food. For patients with moderate renal impairment (creatinine clearance of 30-59 mL/min), the dose should not exceed 80 mg/day. For patients with more severe renal impairment (creatinine clearance of 15-29 mL/min), the dose should not exceed 40 mg/day. FETZIMA is not recommended for patients with end stage renal disease. Gradual dose reduction is recommended when discontinuing treatment to avoid discontinuation symptoms.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
FETZIMA is contraindicated in patients who are hypersensitive to levomilnacipran, milnacipran or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. FETZIMA should not be used in combination with MAOIs, including linezolid, an antibiotic, methylene blue, a dye used in certain surgeries, or within two weeks of terminating treatment with MAOIs. Treatment with MAOIs should not be started until 2 weeks after discontinuation of FETZIMA therapy. FETZIMA should not be used in patients with: myocardial infarction or cardiac intervention within the past 12 months, NYHA Class III or IV congestive heart failure, uncontrolled tachyarrhythmia, uncontrolled hypertension, a history of cerebrovascular accident.
Warnings and precautions
Increased risk of self-harm, harm to others, suicidal thinking and behavior with antidepressants use. Closely monitor all antidepressant-treated patients for clinical worsening and for emergence of agitation-type and/or suicidal thoughts and behaviors. Patients should NOT be discontinued abruptly due to risk of discontinuation symptoms. Serotonin toxicity (serotonin syndrome) is a potentially life-threatening condition, especially with concomitant use of other serotonergic drugs or MAOIs. Elevated Blood Pressure and Hypertension: FETZIMA was associated with mean increases in systolic and diastolic blood pressure. Blood pressure should be measured prior to and periodically throughout treatment. Elevated Heart Rate: SNRIs, including FETZIMA, have been associated with increased heart rate. Heart rate should be measured prior to and periodically throughout treatment. Patients with serious or uncontrolled tachyarrhythmias, ischemic heart disease, or congestive heart failure should not receive FETZIMA. Hyponatremia: May occur, especially in elderly patients, those taking diuretics, or who are volume depleted. Abnormal Bleeding: SSRIs and SNRIs, including FETZIMA, may increase the risk of bleeding events. Concomitant use with NSAIDs, ASA, or other anticoagulants may add to this risk. Seizures: Use with caution in patients with a seizure disorder. Angle-Closure Glaucoma: May cause mydriasis, triggering an angle-closure attack in patients with anatomically narrow ocular angles. Activation of Mania/Hypomania: Use cautiously in patients with a history or family history of bipolar disorder, mania, or hypomania. Not approved for use in treating bipolar depression.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 4 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| FETZIMA | 20 MG | CAPSULE (EXTENDED RELEASE) | ABBVIE CORPORATION | MARKETED | 02440970 |
| FETZIMA | 40 MG | CAPSULE (EXTENDED RELEASE) | ABBVIE CORPORATION | MARKETED | 02440989 |
| FETZIMA | 80 MG | CAPSULE (EXTENDED RELEASE) | ABBVIE CORPORATION | MARKETED | 02440997 |
2 · Same class — other molecules in ATC N06AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Venlafaxine | ACT VENLAFAXINE XR · APO-VENLAFAXINE XR · AURO-VENLAFAXINE XR · DOM-VENLAFAXINE XR · +19 more | 90 | 36 | Yes |
| Duloxetine | ACCEL-DULOXETINE · AG-DULOXETINE · APO-DULOXETINE · AURO-DULOXETINE · +24 more | 66 | 36 | Yes |
| Mirtazapine | APO-MIRTAZAPINE · AURO-MIRTAZAPINE · AURO-MIRTAZAPINE OD · AVA-MIRTAZAPINE · +24 more | 64 | 31 | Yes |
| Trazodone | AG-TRAZODONE · APO-TRAZODONE D TABLETS 150MG · APO-TRAZODONE TABLETS 100MG · APO-TRAZODONE TABLETS 50MG · +30 more | 57 | 21 | Yes |
| Desvenlafaxine | AG-DESVENLAFAXINE · APO-DESVENLAFAXINE · APO-DESVENLAFAXINE EXTENDED-RELEASE TABLETS · DESVENLAFAXINE · +8 more | 28 | 20 | Yes |
| Tryptophan | APO-TRYPTOPHAN · DOM-TRYPTOPHAN · PHL-TRYPTOPHAN · PMS-TRYPTOPHAN · +2 more | 20 | 11 | Yes |
| Bupropion | AVA-BUPROPION SR · BUPROPION HCL SR · BUPROPION HCL XL · BUPROPION SR · +13 more | 32 | 9 | Yes |
| Vortioxetine | APO-VORTIOXETINE · TRINTELLIX | 8 | 6 | Yes |
| Vilazodone | APO-VILAZODONE · VIIBRYD | 8 | 6 | Yes |
| Levomilnacipran | FETZIMA | 4 | 4 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N06A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N06AB | Citalopram · Escitalopram · Fluoxetine · Fluvoxamine · Paroxetine · +1 more | 589 | 248 |
| N06AA | Amitriptyline · Amoxapine · Clomipramine · Desipramine · Doxepin · +5 more | 325 | 62 |
| N06AG | Moclobemide | 21 | 4 |
| N06AF | Tranylcypromine | 2 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is FETZIMA called?
Also recorded in Canada as: levomilnacipran (GLOBAL), levomilnacipran hydrochloride (US).
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.